Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of CPX102 inhalation solution in infants with RSV infection
CTR20244959Phase 2Active
- Sponsor
- Sciwind Biosciences
- Start
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of CPX102 in respiratory syncytial virus disease (RSV), sponsored by Sciwind Biosciences. Started Mar 2025; status: active.
02
Drugs
CPX102
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20244959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244959.